Aim Carcinoid tumors of the lung are the tumors originating from the neuroendocrine cells. Surgical excision remains the gold standard for the treatment. Treatment with interventional bronchoscopic excision has also been reported as an alternative option in typical carcinoid tumors of the lung. The aim of this study was to present results and outcomes in patients who were bronchoscopically treated and followed-up. Methods Data of 14 patients, who had undergone bronchoscopic excision due to typical carcinoid tumor of the lung between April 2008 and July 2015 were retrospectively evaluated. Bronchoscopic excision procedures were performed under general anesthesia, while control bronchoscopies were carried out with flexible bronchoscopy. Time between the first and last bronchoscopies was accepted as the follow-up duration. Results A total of 14 patients was evaluated with eight (57.1%) males. Mean age was 43.57±14.07 (23-68) years. The most common symptoms were shortness of breath and coughing. Mean of 5.69±3.35 (2-12) bronchoscopy procedures were performed in the patients during the diagnosis, treatment and follow-up. Mean follow-up duration was 32.0±19.22 months. At the long-term follow-up, two patients developed 50% stenosis and one patient developed granulation tissue in the endobronchial treatment site. None of the patients developed recurrence during the mean 32-month follow-up. Conclusion Endobronchial treatment is a safe and successful treatment method in well selected typical carcinoid tumor cases that are centrally located, having no radiological suspicion of local or distant metastasis, distally visible but not located on the bronchi with a wide base on bronchoscopy.
Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;1647–51.
2.
Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther. 2003;863–77.
3.
Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;1604–20.
4.
Travis W, Rush W, Flieder D, Falk R, Fleming M, Gal A, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;934–44.
5.
Rizzardi G, Marulli G, Bortolotti L, Calabrese F, Sartori F, Rea F. Sleeve resections and bronchoplastic rocedures in typical central carcinoid tumours. Thorac Cardiovasc Surg. 2008;42–5.
6.
Neyman K, Sundset A, Naalsund A, Espinoza A, Solberg S, Kongerud J, et al. Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchology Interv Pulmonol. 2012;29–34.
7.
Cetinkaya E, Aras G, Sokucu S, Ozgül A, Altin S. Treatment of endoluminal typical carcinoid tumor with bronchoscopic techniques. Tuberk Toraks. 2009;427–30.
8.
Dalar L, Ozdemir C, Abul Y, Sokucu S, Karasulu L, Urer H, et al. Endobronchial treatment of carcinoid tumors of the lung. Thorac Cardiovasc Surg. 2016;166–71.
9.
Dincer H, Podgaetz E, Andrade R. Pulmonary Neuroendocrine Tumors: Part II. Treatment Bronchology Interv Pulmonol. 2015;351–6.
10.
Luckraz H, Amer K, Thomas L, Gibbs A, Butchart E. Long-term outcome of bronchoscopically resected endobronchial typical carcinoid tumors. J Thorac Cardiovasc Surg. 2006;113–5.
11.
Brokx H, Risse E, Paul M, Grünberg K, Golding R, Kunst P, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg. 2007;973–8.
12.
Cao C, Yan T, Kennedy C, Hendel N, Bannon P, Mccaughan B. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann Thorac Surg. 2011;339–43.
13.
Filosso P, Guerrera F, Evangelista A, Welter S, Thomas P, Casado P, et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur J Cardiothorac Surg. 2015;441–7.
14.
Travis W. Advances in neuroendocrine lung tumors. Ann Oncol. 2010;65–71.
15.
Sutedja T, Schreurs A, Vanderschueren R, Kwa B, Vd Werf T, Postmus P. Bronchoscopic therapy in patients with intraluminal typical bronchial carcinoid. Chest. 1995;556–8.
16.
Cavaliere S, Foccoli P, Toninelli C. Curative bronchoscopic laser therapy for surgically resectable tracheobronchial tumors: personal experience. Bronchology Interv Pulmonol. 2002;90–5.
17.
Cavaliere S, Venuta F, Foccoli P, Toninelli C, Face L, B. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest. 1996;1536–42.
18.
Cömert S, Parmasız E, Çağlayan B, Gülseven H, Salepci B, Fidan A. Typical carcinoid and benign endobronchial tumour cases treated with Interventional bronchoscopic techniques. Eurasian J Pulmonol. 2013;39–44.
Karasulu L, Altin S, Dalar L, Sökücü S, Simşek N. Two typical carcinoid cases treated by endobronchial approach. Tuberk Toraks. 2009;212–7.
21.
Detterbeck F. Management of carcinoid tumors. Ann Thorac Surg. 2010;998–1005.
22.
Phan A, Oberg K, Choi J, Harrison L, Hassan M, Strosberg J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;784–98.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
